COPE, COPI coat complex subunit epsilon, 11316

N. diseases: 34; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.020 Biomarker phenotype BEFREE This study modelled the longer-term cost-effectiveness of five parenting interventions delivered in a Swedish context: Comet, Connect, the Incredible Years (IY), COPE, bibliotherapy, and a waitlist control, for the prevention of persistent behavior problems. 31790442 2019
CUI: C0001956
Disease: Alcohol Use Disorder
Alcohol Use Disorder
0.020 Biomarker disease BEFREE COPE was delivered via telehealth to treat one black female veteran with combat trauma and alcohol use disorder. 28118514 2017
CUI: C0233514
Disease: Abnormal behavior
Abnormal behavior
0.020 Biomarker phenotype BEFREE Study participants from a comprehensive cancer center were asked to complete a series of instruments that measured their perception of the patient's cognitive dysfunction (revised memory and behavior problems checklist, RMBC), their own personal resilience (Resilience Scale, RS), and their utilization of a broad range of coping responses (COPE inventory and Emotional-Approach Coping scale). 27921222 2017
Malignant neoplasm of gastrointestinal tract
0.020 Biomarker disease BEFREE Methods We assessed patients' self-reported health status and treatment goal (Prognosis and Treatment Perceptions Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), and mood (Hospital Anxiety and Depression Scale) within 8 weeks of incurable lung or GI cancer diagnosis. 28574777 2017
Malignant neoplasm of gastrointestinal tract
0.020 Biomarker disease BEFREE We sought to validate seven subscales of the Brief COPE in a large sample of patients newly diagnosed with incurable lung and noncolorectal gastrointestinal cancers (N = 350). 27725249 2017
CUI: C0815107
Disease: psychological distress
psychological distress
0.020 Biomarker disease BEFREE Measures included IBS severity (Irritable Bowel Syndrome Severity Scoring System), coping patterns (Carver Brief COPE), visceral sensitivity (Visceral Sensitivity Index), illness perceptions (Brief Illness Perceptions Questionnaire), psychological distress (Depression, Anxiety and Stress Scale), and quality of life (IBS Quality of Life scale; IBS-QoL). 27045996 2017
CUI: C0815107
Disease: psychological distress
psychological distress
0.020 Biomarker disease BEFREE Participants completed the Brief COPE and measures assessing quality of life (QOL) (Functional Assessment of Cancer Therapy-General) and psychological distress (Hospital Anxiety and Depression Scale) within eight weeks of diagnosis of incurable cancer. 27725249 2017
CUI: C0015672
Disease: Fatigue
Fatigue
0.010 Biomarker phenotype BEFREE Fatigue and COPE denial were predictors of higher LTP information preference in a multivariate model. 31655266 2020
CUI: C0030193
Disease: Pain
Pain
0.010 Biomarker phenotype BEFREE Improvement in kinesiophobia after surgery was less likely with higher pre-operative perceived pain frequency (OR 0.23 CI 0.06, 0.71; p=0.009) and higher COPE-denial scores (OR 0.43 CI 0.21, 0.88; p=0.02). 31563440 2020
CUI: C0036341
Disease: Schizophrenia
Schizophrenia
0.010 Biomarker disease BEFREE The data were collected by using schedule for affective disorders and schizophrenia for school-age children-present and lifetime version, kid-coping orientation to problems experienced (Kid-COPE), social support appraisals scale (SSAS), and COPE. 31816196 2020
CUI: C4285782
Disease: Kinesiophobia
Kinesiophobia
0.010 Biomarker disease BEFREE Improvement in kinesiophobia after surgery was less likely with higher pre-operative perceived pain frequency (OR 0.23 CI 0.06, 0.71; p=0.009) and higher COPE-denial scores (OR 0.43 CI 0.21, 0.88; p=0.02). 31563440 2020
CUI: C0005586
Disease: Bipolar Disorder
Bipolar Disorder
0.010 Biomarker disease BEFREE Predominant polarity in bipolar disorder patients: The COPE bipolar sample. 30826493 2019
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.010 GeneticVariation disease BEFREE Seventy individuals with PD (35 females and 35 males) were assessed with the Brief COPE scale, Life Orientation Test-Revised, and Center for Epidemiological Studies Depression Scale. 29557181 2019
CUI: C0033860
Disease: Psoriasis
Psoriasis
0.010 Biomarker disease BEFREE The severity of psoriasis was assessed by the Psoriasis Area and Severity Index (PASI), the Dermatology Life Quality Index (DLQI) was used for quality of life assessment, and the COPE questionnaire was used for determination of coping strategies used by psoriasis patients. 31616215 2019
CUI: C0038436
Disease: Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorder
0.010 Biomarker disease BEFREE Intent-to-treat analyses revealed that COPE, in comparison to RP, resulted in significantly greater reductions in CAPS (d = 1.4, p < .001) and PCL-M scores (d = 1.3, p = .01), as well as higher rates of PTSD diagnostic remission (OR = 5.3, p < .01). 30529244 2019
CUI: C4042834
Disease: Compassion Fatigue
Compassion Fatigue
0.010 Biomarker disease BEFREE Validated measures of compassion fatigue and satisfaction (Professional Quality of Life Scale V [ProQOLV]), coping (Brief COPE), and resilience (Connor-Davidson Resilience Scale-2) were evaluated preprogram and at two, four, and six months postprogram, with resilience and coping style measured at baseline and at six months postprogram. 31007264 2019
CUI: C0026603
Disease: Motion Sickness
Motion Sickness
0.010 GeneticVariation disease BEFREE Compared to the Maladaptive group, the individuals of the Adaptive group scored higher on Boredom Susceptibility (i.e., a subscale of the Sensation Seeking Scale), lower on scales of susceptibility to motion sickness (MSSQ-Short) and tended to score lower on Instrumental Support Seeking (i.e., a subscale of the Brief COPE). 29662460 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung
0.010 GeneticVariation disease BEFREE In this prospective study, a cohort of 50 patients were evaluated using the COPE scale, Generalized Anxiety Disorder Questionnaire 7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9), both prior to and 1 month after learning about their lung cancer diagnosis. 29379318 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.010 GeneticVariation disease BEFREE In this prospective study, a cohort of 50 patients were evaluated using the COPE scale, Generalized Anxiety Disorder Questionnaire 7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9), both prior to and 1 month after learning about their lung cancer diagnosis. 29379318 2018
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung
0.010 GeneticVariation disease BEFREE In this prospective study, a cohort of 50 patients were evaluated using the COPE scale, Generalized Anxiety Disorder Questionnaire 7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9), both prior to and 1 month after learning about their lung cancer diagnosis. 29379318 2018
CUI: C3160814
Disease: Cannabis use
Cannabis use
0.010 Biomarker disease BEFREE In the SEM analysis, female sex and Asian ethnicity directly predicted future ARBs (beta weights 0.10 and -0.11, respectively), while all other variables had indirect impacts on ARBs through alcohol quantities (beta weights ~ 0.23 for European American ethnicity and low LR, 0.21 for cannabis use and COPE, and 0.44 for PEER). 28876407 2018
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.010 Biomarker disease BEFREE In a pilot study, we identified autoantibodies against the coatomer protein complex, subunit epsilon [circulating anti-coatomer protein complex subunit epsilon autoantibody (COPE-Ab)], a cytosolic complex that mediates protein transport in the Golgi compartment, as a potential novel biomarker of atherosclerosis. 27923433 2017
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.010 Biomarker disease BEFREE In a pilot study, we identified autoantibodies against the coatomer protein complex, subunit epsilon [circulating anti-coatomer protein complex subunit epsilon autoantibody (COPE-Ab)], a cytosolic complex that mediates protein transport in the Golgi compartment, as a potential novel biomarker of atherosclerosis. 27923433 2017
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.010 Biomarker disease BEFREE Two hundred forty-four white and African American patients in Virginia and Ohio who received a diagnosis of CRC and who experienced symptoms prior to diagnosis were administered a semistructured interview and the Brief COPE questionnaire. 27044057 2017
CUI: C0022104
Disease: Irritable Bowel Syndrome
Irritable Bowel Syndrome
0.010 Biomarker disease BEFREE Measures included IBS severity (Irritable Bowel Syndrome Severity Scoring System), coping patterns (Carver Brief COPE), visceral sensitivity (Visceral Sensitivity Index), illness perceptions (Brief Illness Perceptions Questionnaire), psychological distress (Depression, Anxiety and Stress Scale), and quality of life (IBS Quality of Life scale; IBS-QoL). 27045996 2017